LUMOS PHARMA INC (LUMO)
US55028X1090 - Common Stock
LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lumos Pharma (NASDAQ:LUMO) just reported results for the first quarter of 2024....
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and...
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare...
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate...
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate...
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share the fourth quarter of 2023.
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lumos Pharma (NASDAQ:LUMO) just reported results for the fourth quarter of 2023...
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2...
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate...
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate...
Lumos Pharma promotes Pisit Pitukcheewanont to chief medical officer (NASDAQ:LUMO)
Lumos Pharma promotes Pisit Pitukcheewanont to Chief Medical Officer, further strengthening their leadership team in global clinical development.
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for...
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
Webinar to be Held December 6, 2023 at 1:30pm EST
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
Webinar to be Held December 6, 2023 at 1:30pm EST...
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones.
Lumos stock rockets nearly 100% in after-hours trading on study updates (LUMO)
Lumos Pharma's (LUMO) stock rocketed nearly 100% in after-hours trading Tuesday after it reported that two Phase 2 studies for its drug LUM-201 met their primary endpoints.
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3...
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3...